Opendata, web and dolomites

ORGANTRANS SIGNED

Controlled Organoids transplantation as enabler for regenerative medicine translation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ORGANTRANS" data sheet

The following table provides information about the project.

Coordinator
CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT 

Organization address
address: RUE JAQUET DROZ 1
city: NEUCHATEL
postcode: 2000
website: www.csem.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 6˙301˙156 €
 EC max contribution 6˙301˙156 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT CH (NEUCHATEL) coordinator 1˙147˙441.00
2    UNIVERSITEIT UTRECHT NL (UTRECHT) participant 1˙357˙397.00
3    REGENHU SA CH (VILLAZ-ST-PIERRE) participant 1˙162˙717.00
4    KUGELMEIERS AG CH (ERLENBACH) participant 968˙750.00
5    VIB BE (ZWIJNAARDE - GENT) participant 602˙125.00
6    DWI LEIBNIZ-INSTITUT FUR INTERAKTIVE MATERIALIEN EV DE (AACHEN) participant 532˙725.00
7    KING'S COLLEGE LONDON UK (LONDON) participant 272˙500.00
8    AMIRES SRO CZ (PRAHA 6) participant 257˙500.00

Map

 Project objective

End-stage liver failure is a major healthcare challenge. Liver diseases account for approximately 2 million deaths per year worldwide. Liver transplantation is the most effective way to re-establish a liver with normal functions for various diseases including acute liver failure or liver malignancies. Currently, less than 10% of global transplantation needs are met and the gap between patients on transplant waiting lists and available donor organs is steadily increasing. ORGANTRANS proposes a disruptive alternative to donor organs for patients with chronic or end-stage liver diseases who have still to isolate autologous liver stem cells. Driven by a need of leading European transplant centers, ORGANTRANS will tackle current obstacles for liver regenerative medicine by combining advanced know-how in cell biology, biomaterials, bioengineering, automation, standardization and clinical translation. ORGANTRANS will develop a liver tissue printing platform that will be shortly deployed under the “compassionate use exemption” by three leading European transplant centers belonging to the consortium or the External Advisory Board. ORGANTRANS will not only deliver an ATMP, but also platform technologies that can be scaled to other organ systems, as organoid technology is one of the largest parts of regenerative medicine. The project covers the entire value chain (from cell source, tissue engineering, bioprinting, post-processing to testing) allowing for early adoption of its results (product & process) in clinical practice. The platform will first be scaled to Europe and then to the rest of the world.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORGANTRANS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ORGANTRANS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More